Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Parkinson's Disease

Free Subscription 17.10.2022 1 Ann Neurol 1 BMC Neurol 1 J Neural Transm (Vienna) 1 J Neurol Neurosurg Psychiatry 1 J Neuropsychol 2 Mov Disord 1 Nervenarzt 2 Neurobiol Dis 4 Neurology 2 Neurosci Lett 3 PLoS One 2 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. SCHIRINZI T, Maftei D, Passali FM, Grillo P, et al
   Olfactory neuron Prokineticin-2 as a potential target in Parkinson's disease.
   Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26526.
   PubMed         Abstract available
   
   

   
   BMC Neurol

2. FAZLOLLAHI A, Zahmatyar M, Alizadeh H, Noori M, et al
   Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.
   BMC Neurol. 2022;22:383.
   PubMed         Abstract available
   
   

   
   J Neural Transm (Vienna)

3. KANEL P, Spears CC, Roytman S, Koeppe RA, et al
   Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis.
   J Neural Transm (Vienna). 2022 Oct 12. pii: 10.1007/s00702-022-02547.
   PubMed         Abstract available
   
   

   
   J Neurol Neurosurg Psychiatry

4. DRAZICH-TAYLOR EHS, Todd E, Convery R, Bocchetta M, et al
   Q351R MAPT mutation is associated with a mixed 3R/4R tauopathy and a slowly progressive cognitive, behavioural and parkinsonian syndrome.
   J Neurol Neurosurg Psychiatry. 2022 Oct 13. pii: jnnp-2022-329330.
   PubMed        
   
   

   
   J Neuropsychol

5. READMAN MR, Crawford TJ, Linkenauger SA, Bek J, et al
   Motor imagery vividness and symptom severity in Parkinson's disease.
   J Neuropsychol. 2022 Oct 13. doi: 10.1111/jnp.12293.
   PubMed         Abstract available
   
   

   
   Mov Disord

6. HULZINGA F, Seuthe J, D'Cruz N, Ginis P, et al
   Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease.
   Mov Disord. 2022 Oct 14. doi: 10.1002/mds.29238.
   PubMed         Abstract available
   
   
7. CLERET DE LANGAVANT L, Roze E, Petit A, Tressieres B, et al
   Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
   Mov Disord. 2022 Oct 10. doi: 10.1002/mds.29222.
   PubMed         Abstract available
   
   

   
   Nervenarzt

8. JOST WH, Buhmann C, Classen J, Eggert K, et al
   [Relevance of COMT inhibitors in the treatment of motor fluctuations].
   Nervenarzt. 2022;93:1035-1045.
   PubMed         Abstract available
   
   

   
   Neurobiol Dis

9. PUIGROS M, Calderon A, Perez-Soriano A, de Dios C, et al
   Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease.
   Neurobiol Dis. 2022;174:105885.
   PubMed         Abstract available
   
   
10. RYU DW, Yoo SW, Oh YS, Lee KS, et al
    Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes.
    Neurobiol Dis. 2022;174:105883.
    PubMed         Abstract available
    
    

    
    Neurology

11. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
    Planning for Prevention of Parkinson Disease: Now Is the Time.
    Neurology. 2022;99.
    PubMed         Abstract available
    
    
12. KIM R, Lee TL, Lee H, Ko DK, et al
    Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease: A Meta-analysis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201453.
    PubMed         Abstract available
    
    
13. BECKER S, Bode M, Brockmann K, Gasser T, et al
    Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease: A Longitudinal Cohort Study.
    Neurology. 2022 Sep 2. pii: WNL.0000000000201201.
    PubMed         Abstract available
    
    
14. ZHANG Y, He X, Mo C, Liu X, et al
    Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201204.
    PubMed         Abstract available
    
    

    
    Neurosci Lett

15. YU Z, Huang L, Xia Y, Cheng S, et al
    Analysis of the m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
    Neurosci Lett. 2022 Oct 6:136907. doi: 10.1016/j.neulet.2022.136907.
    PubMed         Abstract available
    
    
16. ZHANG X, Wang S, Li X, Li X, et al
    Hemoglobin-binding alpha-synuclein levels in erythrocytes are elevated in patients with multiple system atrophy.
    Neurosci Lett. 2022;789:136868.
    PubMed         Abstract available
    
    

    
    PLoS One

17. TORRADO JC, Husebo BS, Allore HG, Erdal A, et al
    Digital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson's disease: Protocol of the mixed method, cyclic ActiveAgeing study.
    PLoS One. 2022;17:e0275747.
    PubMed         Abstract available
    
    
18. DE GOES MCR, Sarmento A, Lima I, Lyra M, et al
    After-effects of thixotropic conditionings on operational chest wall and compartmental volumes of patients with Parkinson's disease.
    PLoS One. 2022;17:e0275584.
    PubMed         Abstract available
    
    
19. MIKOLAIZAK AS, Rochester L, Maetzler W, Sharrack B, et al
    Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol.
    PLoS One. 2022;17:e0269615.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. MORTEN MJ, Sirvio L, Rupawala H, Mee Hayes E, et al
    Quantitative super-resolution imaging of pathological aggregates reveals distinct toxicity profiles in different synucleinopathies.
    Proc Natl Acad Sci U S A. 2022;119:e2205591119.
    PubMed         Abstract available
    
    
21. WANG X, Rimal S, Tantray I, Geng J, et al
    Prevention of ribosome collision-induced neuromuscular degeneration by SARS CoV-2-encoded Nsp1.
    Proc Natl Acad Sci U S A. 2022;119:e2202322119.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: